UK markets closed

PharmaEssentia Corporation (6446.TWO)

Taipei Exchange - Taipei Exchange Delayed price. Currency in TWD
Add to watchlist
96.90+0.20 (+0.21%)
At close: 1:30PM CST

PharmaEssentia Corporation

No. 3, park Street
2nd Floor-5 Nangang District
Taipei 115
Taiwan
886 2 2655 7688
http://www.pharmaessentia.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Ching-Leou Teng Ph.D.Chairman & Chief Pharmaceutical OfficerN/AN/AN/A
Mr. Ko-Chung LinFounder, CEO & Chief Strategy OfficerN/AN/AN/A
Mr. Chan-Kou HwangPres, GM & DirectorN/AN/AN/A
Ms. Snow ChangAccounting Mang. & Sr. Mang. of Fin.N/AN/AN/A
Dr. Albert QinChief Medical OfficerN/AN/AN/A
Narihisa MiyachiHead of Japan Medical AffairsN/AN/AN/A
Mr. Yen-Tung LuanChief Operating Officer of Taichung PlantN/AN/AN/A
Dr. Raymond W. UrbanskiHead of Clinical Devel. & Medical Affairs for U.S. SubsidiaryN/AN/A1959
Wu Kuo-HsiungChief of Taichung PlantN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.

Description

PharmaEssentia Corporation engages in the research, development, production, and sale of therapeutic products for the treatment of human diseases. Its products include ropeginterferon alfa-2b that is used for the treatment of polycythemia vera, essential thrombocythemia, and hepatitis B and C; and Anti-PD-1 antibody for the treatment of cancer. The company also licensed to develop Oraxol for the treatment of breast, advanced gastric, and esophageal cancer; KX01 for the treatment of psoriasis and actinic keratosis. It also focuses on the drug research and development programs in the areas of hematology, infectious disease, oncology, and dermatology. The company has a research collaboration agreement with Axis Therapeutics Limite for the development of T Cell Receptor-T therapy based on the T cell receptor affinity enhancing specific T cell therapy technology platform. PharmaEssentia Corporation was founded in 2003 and is headquartered in Taipei, Taiwan.

Corporate governance

PharmaEssentia Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.